The aim of this trial is to assess the efficacy of LEO 39652 cream compared with LEO 39652 cream vehicle in adults with mild to moderate AD after 3 weeks of treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
Applied for 21 days
proinnovera GmbH, Center of Dermatology Excellence
Münster, Germany
Total sign score at end of treatment
Total Sign Score is defined as the sum of severity scores (4-point scale) of the Individual Sign Scores(erythema, edema/papulation, oozing/crusting, excoriations, lichenification and dryness)for each assessed area.
Time frame: 22 days
Total sign score on limited treatment area
Time frame: 22 days
Investigator's treatment area assessment of disease severity
Time frame: 22 days
Subject´s treatment area assessment of disease severity
Time frame: 22 days
Subject´s assessment of itching
Time frame: 22 days
Transepidermal Water Loss
Time frame: 22 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.